April 16, 2021
April 16, 2021 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab), manufactured by Bristol Myers Squibb. The drug is now indicated for use in combination with fluoropyrimidine
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
International Health Insurance
April 14, 2021
Important Updates for Health Care Providers Regarding Johnson & Johnson’s & Janssen COVID-19 Vaccine
April 14, 2021 - Health Alert Network Update Regarding Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt
April 13, 2021
April 13, 2021 – The U.S. FDA has given accelerated approval to Trodelvy® (sacituzumab govitecan-hziy), manufactured by Gilead, for a new indication to treat locally advanced or
April 13, 2021
April 13, 2021 - Global Reach Health, committed to giving back to the community and beyond, hosted a donation drive this past week, for necessary supplies needed in Guatemala.
April 7, 2021
April 7, 2021 – The U.S. FDA has granted full approval for Trodelvy® (sacituzumab govitecan-hziy), manufactured by Gilead, to treat unresectable locally
April 7, 2021
April 7, 2021
April 6, 2021
April 6, 2021 – The U.S. FDA has approved a new dosing regimen for Erbitux® (cetuximab), manufactured by ImClone. The drug may now be administered once every two weeks to treat